SecBot SecBot

HROW

HARROW, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001360214 Biotech & Drug Discovery
$28.59 +0.15 (+0.53%)
Oct 26 4:00 PM ET · prev $28.44
Market cap
$1.1B
Small cap
Consensus
Buy
93% Buy or better · 15 analysts
Median target
$60.00
+110% · range $45.00–88.00
Next earnings
Nov 16
in 21 days · EPS est. $0.32
1 year
−25.2%
from $38.24 · Oct 27
30 days
−9.5%
from $31.60
52-week range
$27.24–54.80
−48% from high · low Oct 14
Avg volume 20D
605.7K
shares / day
Short interest
7.76M
≈20.7% of shares · +3.7%
Days to cover
12.4
at average volume
Insider net
−$8.1M
4 buyers · 2 sellers · 12 mo
New fund stakes
2
Q2 2026 13F · 0 exits
SecBot read BULLISH 5 reports · 90 days
Balance 1 bearish · 3 bullish · 1 mixed oldest → newest, height = score
Avg score ·High conf. 4/5 ·Next Earnings date, Nov 16, 2026
Strongest BULLISH Harrow closed its acquisition of worldwide rights to TYRVAYA (varenicline solution) nasal spray from…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders bought $468.7K at an average $30.24. 2 insiders sold $8.6M. Price is 5% below their cost.

  • InstitutionsMIXED

    Q2 2026: 21 added (2 new), 15 trimmed or exited. Largest new: Bamco /Ny/ $34.4M, Schonfeld Strategic Advisors $13.6M.

  • AnalystsBULLISH

    14 of 15 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate $0.377 → $0.320 over 90 days. 0 up, 3 down in 30 days.

  • Short sellersSTEADY

    Short interest +3.7% to 7.76M shares. 12.4 days to cover, ≈20.7% of shares.

  • TrendDOWNTREND

    15% below its 50-day average.

Who's buying

13F· Q2 2026
2
new positions
0
exits
$47.9M
in new stakes
FundMoveSharesValue
BAMCO INC /NY/NEW809,350$34.4M
MARSHALL WACE, LLPTRIM369,435$15.7M
CITADEL ADVISORS LLCADD359,874$15.3M
Schonfeld Strategic Advisors LLCNEW319,625$13.6M
SUSQUEHANNA INTERNATIONAL GROUP, LLPTRIM190,116$8.1M
GOLDMAN SACHS GROUP INCTRIM154,777$6.6M
ROYCE & ASSOCIATES LPDOUBLED154,587$6.6M
FIRST TRUST ADVISORS LPTRIM100,315$4.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 93% rate it Buy or better
Strong Buy6Buy8Hold1Sell0Strong Sell0
12-month targets · 8 analysts

Price is below the lowest target. Median implies +110%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 7, 2026BTIG
REITERATE
REITERATEBuy
Sep 9, 2026Leerink Partners
INITIATE
INITIATEOutperform
Aug 11, 2026BTIG
REITERATE
REITERATEBuy
Jul 21, 2026BTIG
REITERATE
REITERATEBuy
May 13, 2026Cantor Fitzgerald
MAINTAIN
MAINTAINOverweight
May 12, 2026BTIG
REITERATE
REITERATEBuy

Insider ledger

Form 4
$468.7K
bought · 4 insiders
$8.6M
sold · 2 insiders
−5.5%
vs their $30.24 cost
DateInsiderTypeValue
Aug 14, 2026
Shojaei Amir
CHIEF SCIENTIFIC OFFICER
EXERCISE$404.6K
Aug 14, 2026
Shojaei Amir
CHIEF SCIENTIFIC OFFICER
SELL$450.0K
Jun 18, 2026
Graves Adrienne L
Director
AWARD5,248 sh
Jun 18, 2026
SILVERNAIL LAUREN P
Director
AWARD5,248 sh
Jun 18, 2026
Sternberg Perry J.
Director
AWARD5,248 sh
May 18, 2026
Graves Adrienne L
Director
BUY$31.1K
May 18, 2026
SILVERNAIL LAUREN P
Director
BUY$31.0K
May 15, 2026
Shojaei Amir
CHIEF SCIENTIFIC OFFICER
AWARD10,000 sh

Earnings setup

Estimates
Nov 16
reports in 21 days
$0.32
EPS estimate, this quarter
−15%
estimate change, 90 days
0↑ 3↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.32$0.21–$0.48+0.0%$99.1M
Next Q🔒 Fresh data, subscribers only
Current FY$0.43$0.14–$0.74-3.7%$350.1M
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Sep 30, 2026
7,762,798
shares short
+3.7%
vs prior settlement
12.4
days to cover
≈20.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 5, 2026 SEC
Harrow closed its acquisition of worldwide rights to TYRVAYA (varenicline solution) nasal spray from Viatris…
8-K — Impact 7/10
Oct 5, 2026 Press
Harrow closed its acquisition of TYRVAYA (varenicline solution) nasal spray from Viatris for $30M in cash at closing…
Impact 6/10
Oct 5, 2026 M&A
Harrow Closes Acquisition of TYRVAYA®
First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatme
Aug 14, 2026 Insider
Shojaei Amir acquired via exercise 11,250 shares
CHIEF SCIENTIFIC OFFICER @ $35.96 ($404.6K)
Aug 14, 2026 Insider
Shojaei Amir sold 11,250 shares
CHIEF SCIENTIFIC OFFICER @ $40.00 ($450.0K)
Aug 10, 2026 SEC
Harrow reported Q2 2026 revenue of $70.7M, an 11% YoY increase and a 60% sequential jump, driven by strong branded…
8-K — Impact 6/10
Aug 10, 2026 SEC
No summary provided
PRESS-RELEASE — Impact 8/10
Jul 20, 2026 Press
Harrow presented three studies at ASRS 2026 supporting IHEEZO and BYOOVIZ, including interim randomized data…
Impact 5/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 16, 2026
Earnings date
HROW Q3 2026 Earnings Scheduled — 2026-11-16
Recent
Oct 5, 2026
M&A
Harrow Closes Acquisition of TYRVAYA®
First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow’s Growing Ocular Surface…
Aug 20, 2026
Press release
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections
Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the largest absolute differences in the immediate…
Aug 10, 2026
Earnings
Harrow Announces Second Quarter 2026 Financial Results
Second Quarter 2026 and Selected Highlights:
Aug 10, 2026
Earnings date
HROW Q2 2026 Earnings Scheduled — 2026-08-10
Jul 27, 2026
Earnings
Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 11, 2026 Company to Host Conference Call to Discuss Results…

SecBot reports

12 filings · 4 press releases · 3 bullish · 1 bearish · 5 mixed · 3 neutral
All HROW filing & press-release reports (16)